{
    "ERBB2 (HER2) Mutation Positive": {
        "First-line Therapy": {
            "Trastuzumab deruxtecan": "Progression (See NSCL-29)",
            "Ado-trastuzumab emtansine": "Progression (See NSCL-29)"
        },
        "Progression": {
            "Immunotherapy +/- Chemotherapy": "Progression (See NSCL-29)"
        }
    },
    "footnotes": {
        "1": "See Principles of Systemic Therapy (NSCL-F)."
    }
}